Am J Psychiatry 160:1823-1829, October 2003
© 2003 American Psychiatric Association
Mortality and Poststroke Depression: A Placebo-Controlled Trial of Antidepressants
Ricardo E. Jorge, M.D.,
Robert G. Robinson, M.D.,
Stephan Arndt, Ph.D., and
Sergio Starkstein, M.D., Ph.D.
OBJECTIVE: Poststroke depression has been shown to increase mortality for more than 5 years after the stroke. The authors assessed whether antidepressant treatment would reduce poststroke mortality over 9 years of follow-up. METHOD: A total of 104 patients were randomly assigned to receive a 12-week double-blind course of nortriptyline, fluoxetine, or placebo early in the recovery period after a stroke. Mortality data were obtained for all 104 patients 9 years after initiation of the study. Demographic and clinical measurements were collected at 3, 6, 9, 12, 18, and 24 months after the stroke. Survival data were analyzed by using the Kaplan-Meier method. RESULTS: Of the 104 patients, 50 (48.1%) had died by the time of the 9-year follow-up. Of 53 patients who were given full-dose antidepressants, 36 (67.9%) were alive at follow-up, compared with only 10 (35.7%) of 28 placebo-treated patients, a significant difference. Logistic regression analysis showed that the beneficial effect of antidepressants remained significant both in patients who were depressed and in those who were nondepressed at enrollment, after the effects of other factors associated with mortality (i.e., age, coexisting diabetes mellitus, and chronic relapsing depression) were controlled. There were no intergroup differences in severity of stroke, impairment in cognitive functioning and activities of daily living impairment, and other medications received. CONCLUSIONS: Treatment with fluoxetine or nortriptyline for 12 weeks during the first 6 months poststroke significantly increased the survival of both depressed and nondepressed patients. This finding suggests that the pathophysiological processes determining the increased mortality risk associated with poststroke depression last longer than the depression itself and can be modified by antidepressants.
This article has been cited by other articles:
|
|
|
|
 
R. G. Robinson and R. E. Jorge
Prevention of first-episode depression: progress and potential
The British Journal of Psychiatry,
April 1, 2009;
194(4):
296 - 297.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. D. Lane, S. R. Waldstein, H. D. Critchley, S. W. G. Derbyshire, D. A. Drossman, T. D. Wager, N. Schneiderman, M. A. Chesney, J. R. Jennings, W. R. Lovallo, et al.
The Rebirth of Neuroscience in Psychosomatic Medicine, Part II: Clinical Applications and Implications for Research
Psychosom Med,
February 1, 2009;
71(2):
135 - 151.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. G. Robinson, R. E. Jorge, and S. Arndt
Escitalopram, Problem-Solving Therapy, and Poststroke Depression--Reply
JAMA,
October 15, 2008;
300(15):
1758 - 1759.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. G. Robinson, R. E. Jorge, D. J. Moser, L. Acion, A. Solodkin, S. L. Small, P. Fonzetti, M. Hegel, and S. Arndt
Escitalopram and Problem-Solving Therapy for Prevention of Poststroke Depression: A Randomized Controlled Trial
JAMA,
May 28, 2008;
299(20):
2391 - 2400.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Strain and M. Blumenfield
Challenges for Consultation-Liaison Psychiatry in the 21st Century
Psychosomatics,
April 1, 2008;
49(2):
93 - 96.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. C. Steffens, H. Chung, K. R. R. Krishnan, W.T. Longstreth Jr, M. Carlson, and G. L. Burke
Antidepressant Treatment and Worsening White Matter on Serial Cranial Magnetic Resonance Imaging in the Elderly: The Cardiovascular Health Study
Stroke,
March 1, 2008;
39(3):
857 - 862.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Townend, M. Brady, and K. McLaughlan
A Systematic Evaluation of the Adaptation of Depression Diagnostic Methods for Stroke Survivors Who Have Aphasia
Stroke,
November 1, 2007;
38(11):
3076 - 3083.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Narushima, S. Paradiso, D. J. Moser, R. Jorge, and R. G. Robinson
Effect of antidepressant therapy on executive function after stroke
The British Journal of Psychiatry,
March 1, 2007;
190(3):
260 - 265.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Mann
The medical management of depression.
N. Engl. J. Med.,
October 27, 2005;
353(17):
1819 - 1834.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. D. Ried, M. J. Tueth, E. Handberg, S. Kupfer, C. J. Pepine, and the INVEST Study Group
A Study of Antihypertensive Drugs and Depressive Symptoms (SADD-Sx) in Patients Treated With a Calcium Antagonist Versus an Atenolol Hypertension Treatment Strategy in the International Verapamil SR-Trandolapril Study (INVEST)
Psychosom Med,
May 1, 2005;
67(3):
398 - 406.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. G. Walker
Integrative Tumor Board: Recurrent Lymphoma
Integr Cancer Ther,
September 1, 2004;
3(3):
250 - 254.
[PDF]
|
|
|
|
|
|
|
C. E. DEAN
Mortality and Poststroke Depression
Am J Psychiatry,
August 1, 2004;
161(8):
1506 - 1506.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Perspectives on Neuroscience and Behavior
Neuroscientist,
August 1, 2004;
10(4):
277 - 277.
[PDF]
|
|
|
|
|
|
|
R. Ramasubbu
SSRI Treatment-Associated Stroke: Causality Assessment in Two Cases
Ann. Pharmacother.,
July 1, 2004;
38(7):
1197 - 1201.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Jackson, K. DeZee, and E. Berbano
Can Treating Depression Improve Disease Outcomes?
Ann Intern Med,
June 15, 2004;
140(12):
1054 - 1056.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J C Davies, P. R Jackson, J. Potokar, and D. J Nutt
Treatment of anxiety and depressive disorders in patients with cardiovascular disease
BMJ,
April 17, 2004;
328(7445):
939 - 943.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Other articles noted: 14 Nov 2003 to 30 Jan 2004
Evid. Based Nurs.,
April 1, 2004;
7(2):
e2 - e2.
[Full Text]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2003
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
